Quince Therapeutics Faces Delisting Concerns
Ticker: QNCX · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, 8-K
TL;DR
Quince Therapeutics might get delisted, big trouble brewing.
AI Summary
Quince Therapeutics, Inc. filed an 8-K on June 21, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company was formerly known as Cortexyme, Inc. and is incorporated in Delaware.
Why It Matters
This filing indicates potential issues with Quince Therapeutics' compliance with stock exchange listing requirements, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a significant negative event for a publicly traded company.
Key Players & Entities
- Quince Therapeutics, Inc. (company) — Registrant
- Cortexyme, Inc. (company) — Former company name
- June 20, 2024 (date) — Date of earliest event reported
- June 21, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 001-38890 (identifier) — SEC file number
- 90-1024039 (identifier) — IRS Employer Identification No.
- 611 Gateway Boulevard, Suite 273 (address) — Principal executive offices
- South San Francisco, California (location) — Principal executive offices location
- 94080 (zip_code) — Principal executive offices zip code
FAQ
What is the specific reason for Quince Therapeutics' potential delisting?
The filing states it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard,' but does not specify the exact rule or standard not met.
When was the company formerly known as Cortexyme, Inc.?
The company's name was changed from Cortexyme, Inc. on January 4, 2016.
What is Quince Therapeutics' principal executive office address?
The principal executive offices are located at 611 Gateway Boulevard, Suite 273, South San Francisco, California, 94080.
What is the SEC file number for Quince Therapeutics?
The SEC file number is 001-38890.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 20, 2024.
Filing Stats: 813 words · 3 min read · ~3 pages · Grade level 12.9 · Accepted 2024-06-21 16:01:53
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share QNCX The Nasdaq Stock Mar
- $1.00 — ties to maintain a minimum bid price of $1.00 per share (the "Minimum Bid Price Requi
Filing Documents
- d835941d8k.htm (8-K) — 25KB
- 0001193125-24-165631.txt ( ) — 144KB
- qncx-20240620.xsd (EX-101.SCH) — 3KB
- qncx-20240620_lab.xml (EX-101.LAB) — 18KB
- qncx-20240620_pre.xml (EX-101.PRE) — 11KB
- d835941d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Quince Therapeutics, Inc. By: /s/ Dirk Thye Date: June 21, 2024 Name: Dirk Thye Title: Chief Executive Officer 2